Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Proxygen GmbH

Headquarters: Vienna, Austria
Year Founded: 2020
Status: Private
BioCentury | Sep 19, 2023
Emerging Company Profile

Magnet: taking molecular glues beyond protein degradation with $50M

The company discovers small molecules that induce desired protein-protein interactions using an arsenal of screening technologies
BioCentury | Aug 1, 2023
Deals

Pharma deals seek novelty with heavy focus on first in class

An analysis of the products, technologies and targets that have attracted global pharma deals over past 12 months
BioCentury | Apr 6, 2023
Deals

April 5 Quick Takes: Farallon seeking change at Exelixis

Plus: molecular glue deals for Proxygen, BioTheryX and updates from Ginkgo and Protagonist  
BioCentury | Nov 11, 2022
Product Development

Molecular glue degraders: moving beyond IMiDs

Technologies unraveling the relationships between glue structures and conformational changes are opening up new targets and E3 ligases
BioCentury | Jun 4, 2022
Regulation

June 3 Quick Takes: myocarditis risk weighs on Novavax stock

Plus venture money for Vizgen, Watchmaker, Latch Bio, Endpoint Health
BioCentury | Feb 2, 2022
Emerging Company Profile

BioCentury’s 2021 class of emerging companies

An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
BioCentury | Mar 6, 2021
Emerging Company Profile

Proxygen’s knockout take on targeted protein degradation

Emerging Company Profile: Vienna’s Proxygen is taking a ligase-agnostic approach to finding molecular glues with therapeutic effects
Items per page:
1 - 7 of 7